# EDGAR Filing Document

**Accession Number:** 0002123613
**File Stem:** 0001193125-26-274886
**Filing Date:** 2026-6
**Character Count:** 12616
**Document Hash:** c3dbc162a7a64a645f6d955020edbe49
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-274886.hdr.sgml**: 20260618

**ACCESSION NUMBER**: 0001193125-26-274886

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260617

**FILED AS OF DATE**: 20260618

**DATE AS OF CHANGE**: 20260618

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** GIANAKAKOS ANASTASIOS
- **CENTRAL INDEX KEY:** 0001413822

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43354
- **FILM NUMBER:** 261100321

**MAIL ADDRESS:**
- **STREET 1:** 333 ALLERTON AVE.
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Kardigan, Inc.
- **CENTRAL INDEX KEY:** 0002123613
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 932994203
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** C/O KARDIGAN, INC.
- **STREET 2:** 131 OYSTER POINT BLVD., SECOND FLOOR
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (415) 573-3220

**MAIL ADDRESS:**
- **STREET 1:** C/O KARDIGAN, INC.
- **STREET 2:** 131 OYSTER POINT BLVD., SECOND FLOOR
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

## Ex-24

**Power of Attorney**

Know all by these presents that the undersigned hereby constitutes and appoints each of Brianne Puglisi, John B. Moriarty, Jr., Darrin Chang, Christian Formica and Monika Kocinska, and with full power of substitution, as the undersigned's true and lawful attorney-in-fact to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)execute for and on behalf of the undersigned, in the undersigned's capacity as a director and officer of Kardigan, Inc., a Delaware corporation (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this day of June 18, 2026.

<u>/s/ Tassos Gianakakos</u>

Name: Tassos Gianakakos

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>GIANAKAKOS ANASTASIOS<br><sub>(Last) (First) (Middle)</sub><br>C/O KARDIGAN, INC.<br>506 CARNEGIE CENTER DRIVE, SUITE 201<br><sub>(Street)</sub><br>PRINCETON, NJ 08540<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Kardigan, Inc. [ KARD ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-06-17 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_President & CEO_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 49821 | D |  |
| Common Stock | 5636388 | I | By AEG 2021 Trust<sup>(1)</sup> |
| Common Stock | 4778 | I | By Katina Mandas 2024 Qualified Annuity Trust dated April 29, 2024<sup>(2)</sup> |
| Common Stock | 1165732 | I | By MJA Legacy Trust dated May 6, 2020<sup>(3)</sup> |
| Common Stock | 2381519 | I | By KCM 2023 Trust<sup>(4)</sup> |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | <sup>(5)</sup> | 2034-06-05 | Common Stock | 4277389 | $8.00 | D |  |
| Stock Option (right to buy) | <sup>(6)</sup> | 2035-09-30 | Common Stock | 1400974 | $14.71 | D |  |
| Stock Option (right to buy) | <sup>(7)</sup> | 2036-04-06 | Common Stock | 1875641 | $23.90 | D |  |
| Stock Option (right to buy) | <sup>(8)</sup> | 2036-04-06 | Common Stock | 7268112 | $23.90 | D |  |
| Series A Preferred Stock | <sup>(9)</sup> | <sup>(9)</sup> | Common Stock | 28702 | <sup>(9)</sup> | I | By AEG 2021 Trust<sup>(1)</sup> |
| Series A Preferred Stock | <sup>(9)</sup> | <sup>(9)</sup> | Common Stock | 41001 | <sup>(9)</sup> | I | By KCM 2023 Trust<sup>(4)</sup> |
| Series B Preferred Stock | <sup>(9)</sup> | <sup>(9)</sup> | Common Stock | 498692 | <sup>(9)</sup> | I | By spouse<sup>(10)</sup> |

---

### Footnotes:

(1) Represents shares held by AEG 2021 Trust. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

(2) Represents shares held by Katina Mandas 2024 Qualified Annuity Trust dated April 29, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

(3) Represents shares held by MJA Legacy Trust dated May 6, 2020. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

(4) Represents shares held by KCM 2023 Trust. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

(5) The option vests in five equal installments, each of which is tied to the Issuer achieving certain market valuation thresholds at specified levels, and subject to the Reporting Person's continuous service as CEO through June 6, 2027.

(6) The option vests in four installments, with 10% of the shares subject to the option vesting upon achievement of the first specified Issuer market valuation threshold, 30% vesting upon achievement of the second specified Issuer market valuation threshold, 30% vesting upon achievement of the third specified Issuer market valuation threshold, and the remaining 30% vesting upon achievement of the fourth specified Issuer market valuation threshold, in each case subject to the Reporting Person's continuous service as CEO through June 6, 2027.

(7) 25% of the shares subject to this option shall vest and become exercisable on March 25, 2027 with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

(8) The option vests in four installments, with 1,125,385 shares subject to the option vesting upon achievement of the first specified Issuer market valuation threshold, 1,125,385 shares vesting upon achievement of the second specified Issuer market valuation threshold, 2,250,770 shares vesting upon achievement of the third specified Issuer market valuation threshold, and the remaining 2,766,572 shares vesting upon achievement of the fourth specified Issuer market valuation threshold, in each case subject to the Reporting Person's continuous service on each such vesting date.

(9) Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") is convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and will automatically convert into the number of shares shown in Column 3 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering and without payment of consideration. The Preferred Stock has no expiration date.

(10) The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

**Remarks:**
Exhibit 24 - Power of Attorney

**Signature:** /s/ John B. Moriarty, Jr., Attorney-in-Fact  
**Date:** 2026-06-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**